Elif Tuğçe Korkmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elif Tuğçe Korkmaz has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Abdulsamet Sandal
Occupational Diseases Clinic, Ankara Gazi Mustafa Kemal Occupational and Environmental Diseases Hospital, Ankara, Türkiye
1 shared publication - Ahmet Uğur Demir
Department of Pulmonary Diseases, Hacettepe University Faculty of Medicine, Ankara, Türkiye
1 shared publication - Deniz Köksal
Department of Chest Diseases, Hacettepe University Medical Faculty, Ankara, Turkey
1 shared publication - Funda Aksu
Department of Chest Diseases, Ankara Atatürk Sanatoryum Training and Research Hospital, University of Health Sciences, Ankara, Turkiye
1 shared publication - Lütfi Çöplü
Hacettepe University
1 shared publication - Salih Emri
Medicana Hospital, Department of Chest Diseases, İstanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 3 August 2021
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (8) , 544-554
Performance of pulmonary embolism severity index in predicting long-term mortality after acute pulmonary embolism
In this study, we aimed to evaluate the accuracy of the original and simplified pulmonary embolism (PE) severity index (PESI) to predict all-cause mortality after 30 days of acute PE diagnosis up to five years within consecutive sub-periods. Adult patients diagnosed with acute PE between January 1, 2003, and June 30, 2013, were retrospectively included. Data on baseline characteristics and mortality during a five-year follow-up were collected. The study included 414 patients (Male/Female=192/222). The median age at diagnosis was 61.5 (minimum–maximum, 18–93) years. Mortality rates were 13.3% at 30 days, 21.8% at 90 days, 32.6% at one year, and 51.0% at five years. Both stratification into risk classes according to the original PESI and low vs. high-risk classification of original and simplified PESI were significantly correlated with the 30-day, 31–90-day, 91-day-one-year, and one-five-year mortality. Significant PESI predictors for mortality were history of cancer [hazard ratio (HR): 3.31, 95% confidence interval (CI): 1.64–6.68; p=0.001] and heart failure (HR: 2.35, 95% CI: 1.04–5.32, p=0.041) at 31–90-day, history of cancer (HR: 5.45, 95% CI: 2.86–10.40, p<0.001) at 91-day-one-year, advancing age (HR: 1.04, 95% CI: 1.02–1.06, p<0.001) and history of cancer (HR: 5.53, 95% CI: 3.41–8.98, p<0.001) at one-five-year after acute PE diagnosis. All-cause long-term mortality in high-risk patients with acute PE according to original or simplified PESI significantly increased up to five years of follow-up. This survival disadvantage was mainly related to cancer and comorbidities rather than acute clinical manifestations. Future prospective studies are needed to demonstrate the effect of various comorbidities on long-term mortality in these patients.
- 3 August 2021
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (8) , 544-554
Open AccessPerformance of pulmonary embolism severity index in predicting long-term mortality after acute pulmonary embolism
In this study, we aimed to evaluate the accuracy of the original and simplified pulmonary embolism (PE) severity index (PESI) to predict all-cause mortality after 30 days of acute PE diagnosis up to five years within consecutive sub-periods. Adult patients diagnosed with acute PE between January 1, 2003, and June 30, 2013, were retrospectively included. Data on baseline characteristics and mortality during a five-year follow-up were collected. The study included 414 patients (Male/Female=192/222). The median age at diagnosis was 61.5 (minimum–maximum, 18–93) years. Mortality rates were 13.3% at 30 days, 21.8% at 90 days, 32.6% at one year, and 51.0% at five years. Both stratification into risk classes according to the original PESI and low vs. high-risk classification of original and simplified PESI were significantly correlated with the 30-day, 31–90-day, 91-day-one-year, and one-five-year mortality. Significant PESI predictors for mortality were history of cancer [hazard ratio (HR): 3.31, 95% confidence interval (CI): 1.64–6.68; p=0.001] and heart failure (HR: 2.35, 95% CI: 1.04–5.32, p=0.041) at 31–90-day, history of cancer (HR: 5.45, 95% CI: 2.86–10.40, p<0.001) at 91-day-one-year, advancing age (HR: 1.04, 95% CI: 1.02–1.06, p<0.001) and history of cancer (HR: 5.53, 95% CI: 3.41–8.98, p<0.001) at one-five-year after acute PE diagnosis. All-cause long-term mortality in high-risk patients with acute PE according to original or simplified PESI significantly increased up to five years of follow-up. This survival disadvantage was mainly related to cancer and comorbidities rather than acute clinical manifestations. Future prospective studies are needed to demonstrate the effect of various comorbidities on long-term mortality in these patients.